Phase 3 trial of voxelotor for sickle cell disease leg ulcers

Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Voxelotor + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Proportion of participants achieving resolution of target ulcer(s) by Week 12.